15-18 month supplementation with high-dose omega-3 improved markers of non-alcoholic fatty liver disease (NAFLD), according to a recent pilot study in European Journal of Clinical Nutrition. NAFLD patients who raised their blood DHA levels more than 2% showed significant improvements in liver metabolism and hepatic insulin sensitivity.
Supplementation also reduced the amount of new fat deposited in the liver, a process called de novo lipogenesis. Existing liver fat content was also reduced by 26%. Another important finding was that increasing DHA blood levels reduced hepatic (liver), but not whole-body, peripheral insulin sensitivity.